Management of Nausea and Vomiting Chemotherapy-induced in Normandy (NAVI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The objective of this study was to evaluate the various parameters involved in the occurrence of nausea / vomiting during the first cycle of chemotherapy for solid tumors or hematologic among a group of chemotherapy-naive patients, despite anti standardized-emetics protocols.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients treated with first line chemotherapy with intravenous (IV) to solid tumors or hematologic.
Aged over 18 years
With solid tumors or hematologic in first line chemotherapy, administered intravenously,
Able to understand the meaning of the questions
Having given their written consent to participate in the survey.
This does not concern patients who:
Do not give their consent for participation
Do not speak French
Suffer from cognitive deficits
Are under therapy
Must receive a combination of radio-chemotherapy
Present an occlusive syndrome
Metastases (s) brain (s) clinically symptomatic (s) or radiologically proven (s) or a (of) tumor (s) brain (s)
Have been previously treated with chemotherapy
Present a cons-indication to corticosteroids, with anti-serotonin or NK1 receptor inhibitors